2026 / 02

Next Paper
DOI: 10.24075/dc.2026.012
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

REVIEW

Growth factors in medicine: current trends and future prospects

Kalinin EV1 , Chechina PA2 , Yermolaeva SA1,3
About authors

1 Laboratory of Translational Biomedicine,
N. F. Gamaleya Federal Research Centre for Epidemiology and Microbiology, Moscow, Russia

2 Sechenov First Moscow State Medical University, Moscow, Russia

3 Petrovsky Russian Scientific Center for Surgery, Moscow, Russia

Correspondence should be addressed<.b>: Egor V Kalinin
Gamalei St., 18, Moscow, 123098, Russia; ur.kb@roge.ninilak

About paper

Financing: funding from the Russian Scientific Fund 24-45-20006.

Author contribution: Chechina PA — collection and analysis of literature; Kalinin EV — collection and analysis of literature, preparation of the manuscript; Ermolaeva SA — preparation of the manuscript.

Received: 2026-05-29 Accepted: 2026-06-10 Published online: 2026-06-21
|
  1. Tu Y, Li B, Zheng S, Qu G, Li M, Li S et al. Growth factor applications and clinical translation: advances and challenges. Ann Med. 2026; 58(1).
  2. Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel). 2017; 9(5): 52.
  3. Park J, Hwang S, Yoon IS. Advanced Growth Factor Delivery Systems in Wound Management and Skin Regeneration. Molecules. 2017; 22(8): 1259.
  4. Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana MD, López-Mola E, et al. Epidermal growth factor in clinical practice — a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009; 6(5): 331–46.
  5. Miller-Kobisher B, Suárez-Vega D, Velazco de Maldonado G. Epidermal growth factor in aesthetics and regenerative medicine: Systematic review. J Cutan Aesthet Surg. 2021; 14(2): 137–46.
  6. Ministerstvo zdravoohraneniya Rossijskoj Federacii. Gosudarstvennyj reestr lekarstvennyh sredstv. Available from URL: https://grls.minzdrav.gov.ru/Grls_View_ v2.aspx?routingGuid=e622e824-be34-405b-93e4-c80f60757fd6. (accessed: 20.07.2026) Russian.
  7. Ministerstvo zdravoohraneniya Rossijskoj Federacii. Rubrikator klinicheskih rekomendacij Available from: https://cr.minzdrav.gov. ru/. (accessed: 20.07.2026) Russian.
  8. Chernomorec NV, Chur NN, Kondratenko GG, Shkoda MV, Yaroshevich NA & Kozik Yu P. Effektivnost’ i bezopasnost’ preparata Eberprot-p v lechenii troficheskih yazv pri saharnom diabete. Medicinskij zhurnal. 2018; 2(64): 128–32. Russian.
  9. Zaitseva EL, Zhilyaev VM, Galstyan GR. Long-term Follow-up of treatment of chronic foot wounds with recombinant human epidermal growth factor in patients with different complications of diabetes mellitus. Diabetes Mellit. 2021; 23(6): 532–40.
  10. Prudovsky I. Cellular Mechanisms of FGF-Stimulated Tissue Repair. Cells. 2021; 10(7): 1830. Russian.
  11. Ministerstvo zdravoohraneniya Rossijskoj Federacii. Reestr razreshenij na provedenie klinicheskih issledovanij. Available from: https://grls.minzdrav.gov.ru/CIPermitionReg.aspx. (accessed: 20.07.2026) Russian.
  12. Liu Y, Duan M, Zhang D & Xie J. The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin (Shanghai). 2023; 55(5): 701–12.
  13. Issa S, Fayoud H, Shaimardanova A, Sufianov A, Sufianova G, Solovyeva V, et al. Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases. Biomedicines. 2024; 12(8): 1906.
  14. Xu M, Cao H, Wu L. The application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies. Ann Med. 2026; 58(1).
  15. Akopyan VB, Stupin AYu, Habenskij BM, Sergeeva AV, Mordvinova EM. Sposob polucheniya mekhanozavisimogo faktora rosta cheloveka. Patent RU2523908C2. Rossiya. 2012 Jul 10. Russian.
  16. Kumar A, Taghi Khani A, Sanchez Ortiz A & Swaminathan, S. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front Immunol. 2022; 13.
  17. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018; 27(12): 1984–2009.
  18. Cai X, Fu H, Zhao X, Lu J, Jiang Q, Chang Y et al. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. Chin Med J (Engl). 2022; 135(19): 2344–50.
  19. Chandra P, Faizan M, Porwal M, Sharma H & Sachan N. An Overview and Review of Growth Factors in Wound Healing: Emerging Trends and Innovations. Curr Diabetes Rev. 2026; 22(1).
  20. Grosso A, Lunger A, Burger MG, Briquez PS, Mai F, Hubbell JA et al. VEGF dose controls the coupling of angiogenesis and osteogenesis in engineered bone. npj Regen Med. 2023; 8(1): 15.
  21. Kalinin EV, Chalenko YM, Sysolyatina EV, Midiber KY, Gusarov AM, Kechko OI et al. Bacterial hepatocyte growth factor receptor agonist stimulates hepatocyte proliferation and accelerates liver regeneration in a partial hepatectomy rat model. Drug Dev Res. 2021; 82(1): 123–32.
  22. Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease. Physiol Rev. 2016; 96(3): 1025–69.
  23. Jia Y, Guan Z, Liu C, Huang M, Li J, Feng J et al. Staphylococcus aureus β-hemolysin causes skin inflammation by acting as an agonist of epidermal growth factor receptor. Microbiol Spectr. 2024; 12(1): e03210–23.
  24. Loo S, Kam A, Li BB, Feng N, Wang X & Tam JP. Discovery of Hyperstable Noncanonical Plant-Derived Epidermal Growth Factor Receptor Agonist and Analogs. J Med Chem. 2021; 64(11): 7746–59.
  25. 25. Chalenko YM, Sysolyatina EV, Sobyanin KA, Kapkaeva MR, Lavrikova A, Kalinin E.et al. Topical treatment with the bacterium-derived c-Met agonist InlB321/15 accelerates healing in the abrasion wound mouse model. Archives of Dermatological Research. 2018; 310(10): 849–856.
  26. Chalenko Y, Sobyanin K, Sysolyatina E, Midiber K, Kalinin E, Lavrikova A et al. Hepatoprotective Activity of InlB321/15, the HGFR Ligand of Bacterial Origin, in CCI4-Induced Acute Liver Injury Mice. Biomedicines. 2019; 7(2): 29.